Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
125M
-
Shares change
-
+53.1M
-
Total reported value, excl. options
-
$336M
-
Value change
-
+$140M
-
Put/Call ratio
-
0.5
-
Number of buys
-
84
-
Number of sells
-
-47
-
Price
-
$2.68
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2024
185 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2024.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 125M shares
of 207M outstanding shares and own 60.38% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (13.7M shares), Bellevue Group AG (9.94M shares), WASATCH ADVISORS LP (9.13M shares), VANGUARD GROUP INC (8.83M shares), GREAT POINT PARTNERS LLC (8M shares), Woodline Partners LP (7.92M shares), MILLENNIUM MANAGEMENT LLC (5.68M shares), D. E. Shaw & Co., Inc. (5.14M shares), BANK OF AMERICA CORP /DE/ (4.55M shares), and Two Seas Capital LP (4.17M shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.